User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab.

Primary tabs

download
  • Open access
  • PDF
  • 306.31 K
Demoulin, Nathalie [UCL] Scohy, Anaïs [UCL] Gillion, Valentine [UCL] Godefroid, Nathalie [UCL] Jadoul, Michel [UCL] Morelle, Johann [UCL]

(eng) Patients receiving rituximab are at high risk for life-threatening coronavirus disease 2019 (COVID-19), stressing the need for effective prevention strategies [1]. A two-dose regimen of the BNT162b2 messenger RNA vaccine (Pfizer/BioNTech) confers 95% protection against COVID-19 and elicits a humoral response in 95.5% of the general population [2, 3]. Because rituximab depletes B cells and impairs response to influenza vaccination [4, 5], it is expected to alter immunization after COVID-19 vaccines. [...]

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2021
Language Anglais
Journal information "Clinical kidney journal" - Vol. 14, no. 9, p. 2132-2133 (2021)
Peer reviewed yes
Publisher Oxford University Press ((United Kingdom) Oxford)
issn 2048-8505
e-issn 2048-8513
Publication status Publié
Affiliations UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale
UCL - SSS/IREC/SLUC - Pôle St.-Luc
UCL - SSS/IREC/NEFR - Pôle de Néphrologie
UCL - (SLuc) Service de néphrologie
UCL - (SLuc) Service de microbiologie
UCL - (SLuc) Service de néphrologie pédiatrique
Links
Bibliographic reference Demoulin, Nathalie ; Scohy, Anaïs ; Gillion, Valentine ; Godefroid, Nathalie ; Jadoul, Michel ; et. al. Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab.. In: Clinical kidney journal, Vol. 14, no. 9, p. 2132-2133 (2021)
Permanent URL http://hdl.handle.net/2078.1/259741